Overview

The aging of the population coupled with more active lifestyles invariably results in the degradation of various tissues throughout the body, impacting one’s appearance and quality of life. Parcell’s regenerative therapeutics target joint and dermal tissues that are most impacted by age and physical activity. Our therapeutic initiatives are based on our broad, proprietary and patented autologous and allogeneic ELA stem cell technology with a strategic development focus in three major and distinct areas:

• Diseases of the spine where ELA cells can be administered locally to generate new bone where fusion is required.
• Orthopedic diseases and injuries, with a specific focus on the potential repair of both articular and meniscal cartilage through the local administration of ELA cells to the site of injury.
• Dermal tissue damage due to aging or excessive sun exposure, where ELA cells can be injected into the affected area to enhance collagen and elastin.

In addition to the programs described above, Parcell has an active Research and Development Pipeline dedicated to harness the full potential of the ELA cell.